In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease

C T Briels; C J Stam; P Scheltens; S Bruins; I Lues; A A Gouw

doi:10.1016/j.clinph.2019.09.014

In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease

C T Briels, C J Stam, P Scheltens, S Bruins, I Lues, A A Gouw

Research output: Contribution to journal › Article › Academic › peer-review

77 Downloads (Pure)

Abstract

OBJECTIVE: In clinical trials in Alzheimer's Disease (AD), an improvement of impaired functional connectivity (FC) could provide biological support for the potential efficacy of the drug. Electroencephalography (EEG) analysis of the SAPHIR-trial showed a treatment induced improvement of global relative theta power but not of FC measured by the phase lag index (PLI). We compared the PLI with the amplitude envelope correlation with leakage correction (AEC-c), a presumably more sensitive FC measure.

METHODS: Patients with early AD underwent 12 weeks of placebo or treatment with PQ912, a glutaminylcyclase inhibitor. Eyes-closed task free EEG was measured at baseline and follow-up (PQ912 n = 47, placebo n = 56). AEC-c and PLI were measured in multiple frequency bands. Change in FC was compared between treatment groups by using two models of covariates.

RESULTS: A significant increase in global AEC-c in the alpha frequency band was found with PQ912 treatment compared to placebo (p = 0.004, Cohen's d = 0.58). The effect remained significant when corrected for sex, country, ApoE ε4 carriage, age, baseline value (model 1; p = 0.006) and change in relative alpha power (model 2; p = 0.004).

CONCLUSIONS: Functional connectivity in early AD, measured with AEC-c in the alpha frequency band, improved after PQ912 treatment.

SIGNIFICANCE: AEC-c may be a robust and sensitive FC measure for detecting treatment effects.

Original language	English
Pages (from-to)	88-95
Number of pages	8
Journal	Clinical Neurophysiology
Volume	131
Issue number	1
Early online date	4 Nov 2019
DOIs	https://doi.org/10.1016/j.clinph.2019.09.014
Publication status	Published - 1 Jan 2020

Access to Document

10.1016/j.clinph.2019.09.014

In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s diseaseAccepted author manuscript, 484 KBLicence: CC BY-NC-ND

Cite this

@article{2fa40f117c2048e2aa1bd1012c5b0605,

title = "In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease",

abstract = "OBJECTIVE: In clinical trials in Alzheimer's Disease (AD), an improvement of impaired functional connectivity (FC) could provide biological support for the potential efficacy of the drug. Electroencephalography (EEG) analysis of the SAPHIR-trial showed a treatment induced improvement of global relative theta power but not of FC measured by the phase lag index (PLI). We compared the PLI with the amplitude envelope correlation with leakage correction (AEC-c), a presumably more sensitive FC measure.METHODS: Patients with early AD underwent 12 weeks of placebo or treatment with PQ912, a glutaminylcyclase inhibitor. Eyes-closed task free EEG was measured at baseline and follow-up (PQ912 n = 47, placebo n = 56). AEC-c and PLI were measured in multiple frequency bands. Change in FC was compared between treatment groups by using two models of covariates.RESULTS: A significant increase in global AEC-c in the alpha frequency band was found with PQ912 treatment compared to placebo (p = 0.004, Cohen's d = 0.58). The effect remained significant when corrected for sex, country, ApoE ε4 carriage, age, baseline value (model 1; p = 0.006) and change in relative alpha power (model 2; p = 0.004).CONCLUSIONS: Functional connectivity in early AD, measured with AEC-c in the alpha frequency band, improved after PQ912 treatment.SIGNIFICANCE: AEC-c may be a robust and sensitive FC measure for detecting treatment effects.",

keywords = "AEC-c, Alzheimer's Disease, Clinical trial, Functional connectivity, Outcome measure, PLI",

author = "Briels, {C T} and Stam, {C J} and P Scheltens and S Bruins and I Lues and Gouw, {A A}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/j.clinph.2019.09.014",

language = "English",

volume = "131",

pages = "88--95",

journal = "Clinical Neurophysiology",

issn = "1388-2457",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease

AU - Briels, C T

AU - Stam, C J

AU - Scheltens, P

AU - Bruins, S

AU - Lues, I

AU - Gouw, A A

PY - 2020/1/1

Y1 - 2020/1/1

N2 - OBJECTIVE: In clinical trials in Alzheimer's Disease (AD), an improvement of impaired functional connectivity (FC) could provide biological support for the potential efficacy of the drug. Electroencephalography (EEG) analysis of the SAPHIR-trial showed a treatment induced improvement of global relative theta power but not of FC measured by the phase lag index (PLI). We compared the PLI with the amplitude envelope correlation with leakage correction (AEC-c), a presumably more sensitive FC measure.METHODS: Patients with early AD underwent 12 weeks of placebo or treatment with PQ912, a glutaminylcyclase inhibitor. Eyes-closed task free EEG was measured at baseline and follow-up (PQ912 n = 47, placebo n = 56). AEC-c and PLI were measured in multiple frequency bands. Change in FC was compared between treatment groups by using two models of covariates.RESULTS: A significant increase in global AEC-c in the alpha frequency band was found with PQ912 treatment compared to placebo (p = 0.004, Cohen's d = 0.58). The effect remained significant when corrected for sex, country, ApoE ε4 carriage, age, baseline value (model 1; p = 0.006) and change in relative alpha power (model 2; p = 0.004).CONCLUSIONS: Functional connectivity in early AD, measured with AEC-c in the alpha frequency band, improved after PQ912 treatment.SIGNIFICANCE: AEC-c may be a robust and sensitive FC measure for detecting treatment effects.

AB - OBJECTIVE: In clinical trials in Alzheimer's Disease (AD), an improvement of impaired functional connectivity (FC) could provide biological support for the potential efficacy of the drug. Electroencephalography (EEG) analysis of the SAPHIR-trial showed a treatment induced improvement of global relative theta power but not of FC measured by the phase lag index (PLI). We compared the PLI with the amplitude envelope correlation with leakage correction (AEC-c), a presumably more sensitive FC measure.METHODS: Patients with early AD underwent 12 weeks of placebo or treatment with PQ912, a glutaminylcyclase inhibitor. Eyes-closed task free EEG was measured at baseline and follow-up (PQ912 n = 47, placebo n = 56). AEC-c and PLI were measured in multiple frequency bands. Change in FC was compared between treatment groups by using two models of covariates.RESULTS: A significant increase in global AEC-c in the alpha frequency band was found with PQ912 treatment compared to placebo (p = 0.004, Cohen's d = 0.58). The effect remained significant when corrected for sex, country, ApoE ε4 carriage, age, baseline value (model 1; p = 0.006) and change in relative alpha power (model 2; p = 0.004).CONCLUSIONS: Functional connectivity in early AD, measured with AEC-c in the alpha frequency band, improved after PQ912 treatment.SIGNIFICANCE: AEC-c may be a robust and sensitive FC measure for detecting treatment effects.

KW - AEC-c

KW - Alzheimer's Disease

KW - Clinical trial

KW - Functional connectivity

KW - Outcome measure

KW - PLI

UR - http://www.scopus.com/inward/record.url?scp=85075192865&partnerID=8YFLogxK

U2 - 10.1016/j.clinph.2019.09.014

DO - 10.1016/j.clinph.2019.09.014

M3 - Article

C2 - 31759193

VL - 131

SP - 88

EP - 95

JO - Clinical Neurophysiology

JF - Clinical Neurophysiology

SN - 1388-2457

IS - 1

ER -

In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease

Abstract

Access to Document

Other files and links

Cite this